Application of Circulating Cell-Free Tumor DNA Profiles for Therapeutic Monitoring and Outcome Prediction in Genetically Heterogeneous Metastatic Melanoma
Renáta Váraljai(Vrije Universiteit Brussel), Alexander Roesch(University of Regensburg), Felix C. E. Vogel(German Cancer Research Center), Batool Shannan(Vrije Universiteit Brussel), Nils von Neuhoff(Leibniz University Hannover), Jérémie Nsengimana(University of Leeds), Dirk Schadendorf(University of Mannheim), Jan‐Malte Placke(Vrije Universiteit Brussel), Antje Sucker(German Cancer Research Center), Teofila Seremet(Vrije Universiteit Brussel), Kilian Wistuba‐Hamprecht(Vrije Universiteit Brussel), Jürgen C. Becker(German Cancer Research Center), Heike Chauvistré(Vrije Universiteit Brussel), Joey Mark S. Diaz(University of Leeds), Andreas Stang(Boston University), Bart Neyns(Molecular Oncology (United States)), Julia Newton‐Bishop(National Cancer Institute), Péter Horn, Klaus Griewank(German Cancer Research Center), Benjamin Weide, Susanne Horn(Vrije Universiteit Brussel)
Cited by 54
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
|Journal of Clinical Oncology|2015|2.1k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
Mutations in <i>GNA11</i> in Uveal Melanoma
|New England Journal of Medicine|2010|1.5k